Curti et al. [18] conducted another study on 17 elderly AML patients in first complete remission to test the clinical efficacy of increasing the number of infused alloreactive NK cells after chemotherapy and IL-2 intake. The gene discussed is IL2; the disease is acute myeloid leukemia.